Both MannKind Corporation (NASDAQ:MNKD) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind Corporation	27.86M	12.06	86.97M	-0.80	0.00
Vertex Pharmaceuticals Incorporated	3.05B	15.85	2.10B	2.07	91.94

Table 1 shows the gross revenue, earnings per share and valuation for MannKind Corporation and Vertex Pharmaceuticals Incorporated.

Profitability

Table 2 provides MannKind Corporation and Vertex Pharmaceuticals Incorporated’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
MannKind Corporation	-312.17%	54.7%	-183.1%
Vertex Pharmaceuticals Incorporated	68.85%	67.5%	43.8%

Volatility & Risk

MannKind Corporation’s volatility measures that it’s 171.00% more volatile than S&P 500 due to its 2.71 beta. Vertex Pharmaceuticals Incorporated’s 1.66 beta is the reason why it is 66.00% more volatile than S&P 500.

Liquidity

MannKind Corporation’s Current Ratio is 0.3 while its Quick Ratio is 0.3. On the competitive side is, Vertex Pharmaceuticals Incorporated which has a 3.4 Current Ratio and a 3.3 Quick Ratio. Vertex Pharmaceuticals Incorporated is better positioned to pay off short and long-term obligations compared to MannKind Corporation.

Analyst Ratings

The following table shown below contains the ratings and recommendations for MannKind Corporation and Vertex Pharmaceuticals Incorporated.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
MannKind Corporation	0	0	2	3.00
Vertex Pharmaceuticals Incorporated	0	2	8	2.80

MannKind Corporation has an average target price of $3.5, and a 95.53% upside potential. Meanwhile, Vertex Pharmaceuticals Incorporated’s average target price is $210, while its potential upside is 11.18%. The information presented earlier suggests that MannKind Corporation looks more robust than Vertex Pharmaceuticals Incorporated as far as analyst view.

Insider & Institutional Ownership

Institutional investors owned 30.6% of MannKind Corporation shares and 98.1% of Vertex Pharmaceuticals Incorporated shares. Insiders owned 0.2% of MannKind Corporation shares. On the other hand, insiders owned about 0.1% of Vertex Pharmaceuticals Incorporated’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
MannKind Corporation	13.91%	36.51%	-2.82%	55.66%	-39.44%	62.26%
Vertex Pharmaceuticals Incorporated	1.99%	-0.46%	6.54%	2.8%	14.6%	14.68%

For the past year MannKind Corporation was more bullish than Vertex Pharmaceuticals Incorporated.

Summary

Vertex Pharmaceuticals Incorporated beats MannKind Corporation on 10 of the 13 factors.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.

Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.